Trial reportBMC pregnancy and childbirth2025
Comparison of the effect of surfactant with and without budesonide on the outcomes of respiratory distress syndrome (RDS) in premature infants: a randomized control trial.
Trial report in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory distress syndrome (RDS) is a common problem in premature infants, whose treatment with surfactant increases their survival. Surfactant does not reduce chronic complications such as chronic lung disease. Using budesonide with surfactant may reduce some of these complications. This study aimed to compare the effect of surfactant with and without budesonide on the outcomes of RDS in infants.
methodsThis double-blind, randomised control trial was conducted from September 2023 to April 2024 in the neonatal intensive care unit of Afzalipour Hospital, Kerman, Iran, on premature infants with a gestational age of less than 32 weeks with RDS requiring surfactant. Infants were randomly assigned to two groups: surfactant alone and surfactant with budesonide (30 neonates in each group). Infants were examined daily by neonatologists and the data was recorded in the study checklist by a nurse; both were unaware of the grouping. Data analysis was done using SPSS software version 26.
resultsThe use of surfactant with budesonide significantly reduced the average duration of ventilation (P = 0.029) compared to surfactant alone. However, this treatment approach did not cause a significant difference in other outcomes, including the need for additional doses of surfactant, intraventricular hemorrhage, pneumothorax, BPD, PIE, sepsis, pulmonary and gastrointestinal bleeding, NEC, the need for inotropes, and mortality between the two groups (P > 0.05).
conclusionThe use of surfactant with budesonide can reduce the duration of ventilation, but has little effect on other outcomes of RDS. The long-term prognosis of this type of treatment should be followed up at the age of 2 years, and more studies are needed to clarify its effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.